Skip to main content

Advertisement

SpringerLink
Log in

Osteoporosis drugs in real-world clinical practice: an analysis of persistence

  • Short Communication
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

The aim of our retrospective cohort study is to analyze the persistence rates in relation to antiosteoporotic drugs using administrative databases in the Campania Region. Patients, aged ≥40 years, were included if at least one prescription for any antiosteoporotic drugs had been filled in between January 1, 2009 and December 31, 2009. Overall, 37,594 patients were incident users of antiosteoporotic drugs. Among them, 15,978 patients had undergone spot-therapies. A total of 2,618 (14.1 %) were classified as switchers. Switching rates were highest for patients taking Alendronate 18.9 or Strontium Ranelate 15.0 and lower for patients taking Ibandronate 12.8 or Risedronate 10.8. In the overall population, 33.5 % of subjects were still on therapy after 6 months. At 1 year, persistence rates were: Ibandronate 21.6 %, Risedronate 15.8 %, Alendronate + Vitamin D 15.7 %, Raloxifene 14.3 %, Alendronate 12.6 % and Strontium Ranelate 5.0 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Piscitelli P, Iolascon G, Gimigliano F, SIOMMMS study group, CERSUM research group et al (2007) Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int 18:211–219

    Article  PubMed  CAS  Google Scholar 

  2. Kanis JA, Burlet N, Cooper C, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428

    Article  PubMed  CAS  Google Scholar 

  3. Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47

    Article  PubMed  Google Scholar 

  4. Wade SW et al (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50:870–875

    Article  PubMed  Google Scholar 

  5. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951

    Article  PubMed  CAS  Google Scholar 

  6. Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968

    Article  PubMed  CAS  Google Scholar 

  7. Rossini M, Bianchi G, Di Munno O, Treatment of Osteoporosis in clinical Practice (TOP) Study Group et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921

    Article  PubMed  CAS  Google Scholar 

  8. Baio G, Barbagallo M, D’Avola G, Di Luccio A, Di Tanna G, Falaschi P, Iolascon G, Malavolta N, Robbiati F, Ulivieri F (2011) Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis. Expert Opin Pharmacother 12(2):257–268 (Review)

    Article  PubMed  CAS  Google Scholar 

  9. De Berardis G, D’Ettorre A, Graziano G et al (2012) The burden of hospitalization related to diabetes mellitus: a population-based study. Nutr Metab Cardiovasc Dis 22(7):605–612

    Article  PubMed  Google Scholar 

  10. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575

    Article  PubMed  Google Scholar 

  11. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928

    Article  PubMed  Google Scholar 

  12. Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Jt Surg Am 90(10):2142–2148

    Article  Google Scholar 

  13. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13

    Article  PubMed  Google Scholar 

  14. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501

    PubMed  Google Scholar 

  15. Tafaro L, Nati G, Leoni E, Baldini R, Cattaruzza MS, Mei M, Falaschi P (2013) Adherence to anti osteoporotic therapies: role and determinants of “spot therapy”. Osteoporos Int 24(8):2319–2323. doi:10.1007/s00198-013-2283-zEpub2013Feb12

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Specialties and Dentistry, Second University of Naples, Naples, Italy

    Giovanni Iolascon, Francesca Gimigliano & Annarita Capaldo

  2. Center of Pharmacoeconomics and Drug Utilization (CIRFF), Department of Pharmacy, “Federico II” University of Naples, Naples, Italy

    Valentina Orlando & Enrica Menditto

  3. IRCCS, SDN Foundation, Naples, Italy

    Carolina Di Somma

Authors
  1. Giovanni Iolascon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Gimigliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Orlando
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annarita Capaldo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carolina Di Somma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enrica Menditto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Iolascon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iolascon, G., Gimigliano, F., Orlando, V. et al. Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin Exp Res 25 (Suppl 1), 137–141 (2013). https://doi.org/10.1007/s40520-013-0127-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40520-013-0127-5

Keywords

Search

Navigation